Article Text
Abstract
Our goals are to (1) set forth and defend a multiprinciple system for selecting individuals who meet trial eligibility criteria to participate in early phase clinical trials testing chimeric antigen receptor (CAR T-cell) for acute lymphoblastic leukaemia when demand for participation exceeds spaces available in a trial; (2) show the relevance of these selection criteria to other breakthrough experimental therapies; (3) argue that distinct distributive justice criteria apply to breakthrough experimental therapies, standard research and healthcare and (4) argue that as evidence of benefit increases, the emphasis of justice in research shifts from protecting subjects from harm to ensuring fair access to benefits.
- Research Ethics
- Allocation of Health Care Resources
- Clinical trials
- Distributive Justice
- Drugs and Drug Industry
Statistics from Altmetric.com
Footnotes
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- What is CAR T-cell therapy?
- Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2
- SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report
- CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome
- Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma
- Cardiotoxicities of novel cancer immunotherapies
- CAR-T treatment for hematological malignancies
- The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
- Neurotoxicity—CAR T-cell therapy: what the neurologist needs to know
- SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity